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Treatment with Thio-TEPA has produced, in a significant number of patients
suffering from very advanced carcinoma of ovary, marked temporary retrogres-
sion ofgrowth and improvement of symptoms; in a few cases temporary clinical
disappearance of growth, ascites and disappearance of symptoms was achieved,
and those patients resumed their normal activities enjoying life for the duration
of control of growth. Our article contains observations made from January
1957 till June 1959, and an attempt of quantitative presentation of clinical
results was made. Our observations confirm and emphasise previous reports.
Triethylene thiophosphoramide (Thio-TEPA) is an alkylating agent struc-
turally related to nitrogen mustard and triethylene melamine and has a similar
cytotoxic effect. The clinical effect appears to differ significantly.
Thio-TEPA was synthesised in the Lederle Laboratories.
Shay et at. (1953) reported marked improvement in some cases of chronic
leukaemia and of Hodgkin's disease which were treated with Thio-TEPA; they
also reported an encouraging response in two patients suffering from metastases
from mammary cancer.
These authors quoted and reviewed briefly the extensive experimental work
of the Lederle group of workers and described their own work which led to the
clinical trial.
Bateman published a detailed report on the clinical effect of Thio-TEPA in
99 cases of advanced malignant solid tumours (Bateman, 1955), and on 380
cases (Bateman, 1958).
Leonard, Israels and Wilkinson (1956) reported the effect of Thio-TEPA on
Hodgkin's granuloma, chronic lymphatic leukaemia, polycythaemia and other
reticuloses.
Many valuable reports have been published since 1953. A monograph of
1266 pages containing a series of papers on the chemistry, biological effects and
clinical results ofalkylating agents was published in April 1958 by the New York
Academy of Science. This monograph also contains studies on the effect of
Thio-TEPA on malignant disease and on haemopoiesis by Wright, Golomb and
Gumport (1958), Ultman, Hayman and Gelhorn (1958), Olson (1958), Shay and
Sun (1958), Bateman (1958), Alpert (1958), Moore (1958), Leone (1958) and other
related papers with references to previous work and to other authors.
The effect of Thio-TEPA on Hodgkin's disease, chronic lymphatic leukaemia
and other reticuloses has been reported to be similar, but not superior, to that
of nitrogen mustard.
A few cases of various groups of solid malignant tumours have been treated
with Thio-TEPA. Only in a very few of these has temporary effect of varyingEFFECT OF THIO-TEPA ON OVARIAN TUMOURS
degree and duration been reported. Further systematic observation and collec-
tion of data is necessary.
Reports have repeatedly been published on marked temporary regression of
tumour and decrease of ascites, with improvement of symptoms, in advanced
carcinoma of the ovary, confirming Bateman's original observations published
first in 1955. Bateman also observed in a large proportion of cases of carcinoma
of breast with secondaries, temporary regression of tumour masses, healing of
ulceration, recalcification ofbone lesions and control of effusions.
Recently Watson and Turner (1959) reported the favourable response of
breast cancer to combined therapy with Thio-TEPA and testosterone propionate.
Thio-TEPA has a marked toxic effect on haemopoietic tissue which results in
reduction of the number of leucocytes and of platelets; excessive doses will lead
to irreversible changes of haemopoietic tissue, which may be fatal. Haemato-
logical control during treatment is therefore essential. In therapeutic doses the
effect on haemopoiesis is reversible on cessation of treatment. Compared with
nitrogen mustard the side effects, such as nausea and vomiting, are very slight
and in most patients absent. Thio-TEPA has been injected intra-venously,
intra-muscularly, into the tumour, into pleural or peritoneal cavity if fluid was
present, and intra-arterially for regional treatment; it has also, though rarely,
been given by mouth.
Bateman (1955) emphasized that Thio-TEPA was most effective when injected
directly into the tumour.
We have treated 33 cases of malignant disease with Thio-TEPA:
Group A-carcinoma ovary-17 cases.
Group B-carcinoma breast-9 cases.
Group C-miscellaneous-8 cases (reticulum cell sarcoma 1, Brill
Symmer's 1, carcinoma cervix 1, carcinoma bronchus 2, post cricoid
carcinoma 1, myxosarcoma 1, secondary adenocarcinoma of groin of
unknown primary +? secondaries in lungs).
Our observations on group B and C will be evaluated separately.
We present here the observations on the effect of Thio-TEPA in 17 cases of
advanced carcinoma of ovary, which were treated in this department from
January 1957 till June 1959. During those 29 months 63 cases were referred to
the Radiotherapy Department and 52 cases were treated either with X-ray and
radium or with X-ray only; most of the cases were referred for post-operative
treatment.
Four of the 17 cases which were treated with Thio-TEPA were referred prior
to January 1957.
All cases treated with Thio-TEPA were suffering from recurrence after surgery
and radiotherapy, or the disease was too widespread for effective X-ray treatment
and were inoperable.
The cases were not selected deliberately. All cases which became known to
one ofthe authors (O. E.) who were suffering from advanced inoperable carcinoma
of ovary and could not be treated with X-ray effectively were treated with Thio-
TEPA; advanced but symptom-free cases were not treated.
It has been our aim to evaluate quantitatively the extent and duration of
objective and subjective improvement.
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For approximate quantitative appreciation of the clinical effect, we have
expressed the degree of subjective and objective improvement in five grades and
return to activity has been expressed separately, as shown in the key to the
graphs.
Of the 17 cases treated 3 are alive and 14 died. Six showed no improvement
(Table I), ofthose six, 3 were in a terminal stage at the start oftreatment and had
only two or one injection.
TABLE I.-Cases in Whom Thio-TEPA had no Effect
Duration
from first
symptom
Case First symptom to first
No. Age and date treatment
12 41 October 1956. 4 months
Enlarged
abdomen
and cough
13 57 December 1957. 10 months
Lassitude
14 29 April 1957. 7 months
Swelling of
abdomen
15 36 August 1957. 3 months
Acute abdominal
pain and
vomiting
Duration
of ob-
servation
from first
treatment
24 weeks
Histology
Pleomorphic
carcinoma
2 weeks Adeno-carcinoma
2 days Granulosa cell
carcinoma
2 weeks Arrhenoblastoma
Degree of
leukopenia
Total dose during
and route treatment
125 mg. +
into tumour
25 mg.
intra-
peritoneal
25 mg.
intra-
peritoneal
50 mg.
intra-
peritoneal
Remarks
Died 24 weeks after
first injection.
- Died 2 weeks after
first injection.
Died 2 days after
first injection.
- Died within 2 weeks
of injection.
16 20 July 1957.
Abdominal
pain
18 months 8 weeks Anaplastic
carcinoma
? arrhenoblastoma
60 mg.
intra-venous
+ Died 8 weeks after
first injection.
17 53 March 1958. 3 months
Cough
12 weeks Adeno-carcinoma 100 mg.
intra-
peritoneal
+ + + Died 12 weeks after
first injection.
Eleven cases showed a varying degree of improvement. Eight showed objec-
tive and subjective improvement. Three cases observed for only 11 to 12 weeks
showed subjective improvement only (Table II).
The following case histories, with graphs, illustrate the clinical effect of
Thio-TEPA.
CASE 1(FIG. 1)
Age 55. Histology: Granulosa cell tumour. First symptom: February
1956, pain in left iliac fossa. July 1956: removal of bilateral carcinomatous
tumours of ovary. The left ovarian tumour was incompletely removed because
of extensive adhesion; secondary nodules on peritoneum and in omentum at
the time of operation.
Post-operative X-ray treatment and one radium application to uterus was
given in August/September 1956.
Prior to treatment with Thio-TEPA: severe abdominal pain; she could
hardly keep any food down because of incessant vomiting. There was a large
30EFFECT OF THIO-TEPA ON OVARIAN TUMOURS 31
tumour arising from the pelvis extending into abdomen to the level of the
umbilicus.
31.1.57 treatment with Thio-TEPA commenced. She was given a course of
55 mg. in 3 injections into tumour over 3 weeks and later further injections as
shown in graph.
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FIG. 1
Degree of clinical improvement
Grade 1. Improvement of symptoms.
2. Disappearance of symptoms.
3. Decrease in size of tumour or decrease of ascites.
4. Clinical disappearance of ascites.
5. Disappearance of tumour, of ascites and of symptoms.
Normal activity L7/// I
Restricted activity f7/7w7-77
Within one week from the start of treatment with Thio-TEPA improvement
commenced, and in the third week vomiting had ceased, pain was markedly
improved and the tumour had become smaller.
In the 9th week she was free from pain. The tumour was greatly reduced
in size and could just be felt above the symphysis. She maintained improvement
for 16 weeks, then the symptoms recurred and the tumour grew again rapidly in
size.
A second course of 4 injections at weekly intervals to a total of 90 mg. was
followed by improvement of pain and slight gain in strength for only 6 weeks,32 0. ENGLANDER AND A. SARANGI
TABLE IL.-CC8es in Whom Thio-TEPA
Time of
Duration from observation
1st symptom to from 1st
First 1st treatment treatment Total dose
Case symptom with Thio-TEPA with Thio-TEPA and route of
No. Age and date in months Histology in weeks administration
1 . 53 February 1956. 11 Granulosa cell 51 240 mg. into tumourand
Pain in left iliac fossa carcinoma intramuscular
2 . 56 April 1956. 29 Ditto 92 455 mg. intraperitoneal
Swelling oflower ab-
domen
44
52
March 1958.
Pain in left abdomen
May 1958,
Swelling of abdomen
5 . 55 December 1955.
Malaise
6 . 54 May 1956.
Pain in right lower
abdomen
7 . 54 October 1958.
Lassitude
8 . 55 December 1958.
Swelling of abdomen
9 45 November 1956.
Pain in left pelvis
10 . 55 December 1957.
Vaginal bleeding
11 . 57 June 1958.
Swelling right groin
8 ,, 47 375 mg. intraperitoneal
and intramuscular
6 Serous papillary 51 150 mg. intraperitoneal
adenocarcinoma
37 Granulosa cell 19 127 mg. intraperitoneal,
carcinoma intravenousandintra-
muscular
33 Papillary cyst- 40 112 - 5 mg. intravenous
adenocarcinoma
4 Papillary adeno- 39 175 mg. intraperitoneal
carcinoma
3 No histology 18 120 mg. intraperitoneal
28 Granulosa cell 30 100 mg. intramuscu-
carcinoma larly
8 Poorly differenti- 16 215 mg. intraperitoneal
ated adeno- and into tumour
carcinoma
7 Papillary adeno- 12 200 mg. intraperitoneal
carcinoma
3
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was Effective in Varying Degree
Clinical effect
Cessation of pain and vomiting and marked
reduction in size of tumour for 15 weeks
Temporary disappearance of tumour ascites
and symptoms-returned to normal acti-
vity. Improvement maintained for 32
weeks. Second course of injections for
recurrence followed by disappearance of
ascites, reduction oftumour and improve-
ment of symptoms for 20 weeks. Third
course oftreatment started for recurrence,
but no improvement observed yet
Considerable regression oftumour. Strength,
appetite improved. Greater sense ofwell-
being
Marked regression in size oftumour. Ascites
disappeared. All symptoms disappeared
-returned to normal activity
Disappearance of oedema of legs. Disten-
sion of veins ofabdominal wall diminish-
ed. Improvement of nausea, vomiting
and pain. Slight gain in appetite and
weight
Retrogression of pelvic tumour. Pain de-
creased. Appetite and strength im-
proved
Ascites decreased. Gained strength. Ap-
petite improved. Sense of well-being
Appetite and strength improved
Degree of
leukopenia
during
treatment
Remarks
June 1 1959
+ + + From 38th week onwards
gradual deterioration.
Died 51 weeks after
first injection
+ + Still under observation.
+ + Alive and well doinglight
housework
++ Free from symptoms.
Enjoying normal life.
+ D Developed recto-vaginal
fistulainthe 11thweek.
Underconsiderationfor
a further course when
white count improves
++++ Improvement main-
tained.
+ Doing her housework and
working as part-time
typist
+ Symptoms improving
Further observations
December 1959
Patient died 19.viii. 59; 92
weeks after the first in-
jection of Thio-TEPA.
Patient died 8.x.59; 47
weeks after the first in-
jection of Thio-TEPA.
Well until August 1959 then
recurrence of growth and
ascites. Further injec-
tions of Thio-TEPA fol-
lowed by disappearance
of symptoms for 8 weeks.
Then rapid progress of
disease and failing
strength.
Patient died 9.vi.59; 19
weeks after the first in-
jection of Thio-TEPA.
Improvement maintained.
Two intramuscular in-
jections of 30 mg. each
were given in December.
Improvement maintained.
Further 140 mg. in 6
intra - peritoneal injec-
tions given.
Patient died 20.vii. 59; 18
weeks after the first in-
jection of Thio-TEPA.
No measurable regression of tumour. + +
Gained strength
Pain and ascites diminished. Sense of well- + +
being started within two weeks following
first injection. Improvement maintained
for 12 weeks. Slight reduction of tumour
noted
Improvement in strength and appetite only + + +
for a short period
3
Improvement of symp- Patient died 4.xi. 59; 30
toms maintained to weeks after the first in-
date jection of Thio-TEPA.
Died 16 weeks after first
injection ofThio-TEPA
Died 12 weeks after first
injectionofThio-TEPA
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then symptoms and signs recurred and she died in the 51st week after the first
injection.
The effect on leucocytes was of particular interest. The number of leucocytes
at the start of treatment was 3000, dropped to 1700 in the 9th week after the
first injection of Thio-TEPA and quickly rose to 7100 when clinical improvement
commenced.
Time of observation was 51 weeks.
CASE 2 (FIG. 2)
Age 56. Histology: well differentiated, probably granulosa cell carcinoma.
First symptom: April 1956, swelling of lower abdomen.
FIG. 2
Degree of clinical improvement - - - - - - - - - - -
Grade 1. Improvement of symptoms.
2. Disappearance of symptoms.
3. Decrease in size of tumour or decrease of ascites.
4. Clinical disappearance of ascites.
5. Disappearance of tumour, of ascites and of symptoms.
Normal activity
Restricted activity _ 77.71 7 A
13.8.56 subtotal hysterectomy and bilateral oophorectomy for bilateral
ovarian carcinoma. Secondary nodules on pelvic peritoneum and peritoneum
overlying the bladder. 13.8.56 2 pints of blood transfused.
September/October 1956 post-operative X-ray treatment and one radium
application to uterus.
Prior to Thio-TEPA: pelvic pain, abdominal distension and bleeding from
the umbilicus on slight trauma. Examination after removal of 3000 ml. ofascites
by paracentesis on 12. 11.57: nodular mass in pouch of Douglas extending into
both sides of pelvis. Secondary tumour, 2 cm. diameter, in umbilicus.
34EFFECT OF THIO-TEPA ON OVARIAN TUMOURS
Commencing on 13th November 1957, she was given the first course of Thio-
TEPA, 3 intra-peritoneal inijections of 25 mg. each, in 3 weeks. She vomited
occasionally during the first 7 days; from the second week onwards she gained
strength, her appetite improved and she felt well. From the 8th week onwards
there was no evidence of disease and she was free from symptoms. Definite
decrease in size ofthe tumour was observed in the 7th week after the first injection
and in the 11th week all growth and ascites had disappeared. She led a normal
life doing all her housework for approximately 8 months, then pain, ascites,
tumour of pelvis and umbilicus reappeared rapidly.
She was given further injections of Thio-TEPA commencing with a course of
4 injections of 25 mg. each in 4 weeks, and later further injections as shown in
Fig. 2.
Six weeks after the start of the second course she again gained in strength,
attained a sense of well-being and her appetite improved; her symptoms disap-
peared completely and she returned to her normal activities for 32 months.
During this period ascites disappeared, the growth had decreased in size but did
not disappear ; then pain and ascites recurred rapidly and frequent paracentesis
became necessary. Further injections were given as shown in the graph.
The patient died 19. 8.59, 92 weeks after the first injection of Thio-TEPA.
CASE 3 (FIG. 3)
Age 44. Histology: granulosa cell carcinoma producing pseudoadenomatous
appearances.
First symptoms: March 1958, pain in left abdomen.
Operation: 24. 9.58: gross ascites, abdomen filled with bilateral multi-
locuilar ovarian cystic tumours with a large amount of solid and friable tissue.
AMetastases on pelvic peritoneum and uterus. Both ovarian newgrowths removed.
Prior to Thio-TEPA: 27. 10.58 ascites; firm mass ofgrowth in upper third of
rectovaginal septum and pouch of Douglas; large mass in left pelvis and a large
mass in left lumbar region extending into left hypochondrium.
Treatment with Thio-TEPA commenced on 10. 11.58: a course of 84 mg.
was given in 5 injections in 10 days, and a second course of 116 mg. commenced 8
weeks after the first injection.
From the 10th day onwards she gained strength, her appetite improved and
later on she felt well and was doing light housework except when ascites had
accumulated. From the 14th week onwards tumour decreased in size but did not
disappear. In the 19th week a paracentesis of abdomen was necessary,
subsequently she was well and doing light housework until the 25th week when
ascites and symptoms recurred. Further injections were given as shown in
Fig. 3.
The patient died 8. 10.59, 47 weeks after the first injection of Thio-TEPA.
CASE 4 (FIG. 4)
Age 52. Histology: serous papillary adenocarcinoma of ovary.
First symptom: May 1958, swellinig of abdomen.
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Operation 13.8.58: 4500 ml. of ascitic fluid removed. Right ovarian cystic
tumour of 12 cm. diameter removed. Peritoneal metastases present.
13.8.58: 4 pints of blood transfused.
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FIG. 3
Degree of clinical improvement
Grade 1. Improvement of symptoms.
2. Disappearance of symptoms.
3. Decrease in size of tumour or decrease of ascites.
4. Clinical disappearance of ascites.
5. Disappearance of tumour, of ascites and of symptoms.
Normal activity __
Restricted activity it y/ 7Z
Post-operative X-ray treatment September/October 1958, could not be
completed because of poor general condition.
Prior to Thio-TEPA: November 1958, examination under anaesthesia after
removal of 5700 ml. of ascites: a mass consisting of matted spherical tumours
filling pelvis and lower abdomen extending into upper abdomen on the right side.
Main symptoms: lassitude and gnawing abdominal pain.
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On 22.11.58 the first course of Thio-TEPA commenced; 100 mg. were given
in 4 intra-peritoneal injections of 25 mg. each at weekly intervals, and she was
given a further 25 mg. in the 16th and 17th week after the first injection.
In the 6th week decrease in size of tumour mass was observed, and in the 10th
week the tumours had disappeared except for one 4 cm. diameter lump at the
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FIG. 4
Degree of clinical improvement --- --- - --- -
Grade 1. Improvement of symptoms.
2. Disappearance of symptoms.
3. Decrease in size of tumour or decrease of ascites.
4. Clinical disappearance of ascites.
5. Disappearance of tumour, of ascites and of symptoms.
Normal activity
Restricted activity F7/ XJ/JA
level ofumbilicus which was still palpable. At that time ascites had disappeared
and did not re-accumulate during the time ofobservation. The lump at the level
of umbilicus continued to decrease in size but did not completely disappear.
From the second week onwards her appetite improved, she gained strength and
attained a sense of well-being, and from the 18th week onwards she could do all
her housework, and was enjoying a normal life.
She remained well and vigorous and the tumours decreased further in size
until August 1959, In August the tumours, ascites and symptoms reappeared.
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A further 3 intra-peritoneal injections of 30 mg. each were given followed by
improvement of symptoms and return to her activity for 8 weeks. Since then
the growth increased in size, she lost strength and flesh rapidly.
CASE 5 (FIG. 5)
Age 55. Histology: granulosa cell carcinoma.
First symptom: December 1955, malaise.
13. 1.56: removal of a large left multilocular cystic ovarian growth.
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FIG. 5
Degree of clinical improvement -
Grade 1. Improvement of symptoms.
2. Disappearance of symptoms.
3. Decrease in size of tumour or decrease of ascites.
4. Clinical disappearance of ascites.
5. Disappearance of tumour, of ascites and of symptoms.
Normal activity f7 77/
Restricted activity t77/ 7/ / Z A7 ,
May 1957: large fixed hard nodular mass of growth in pouch of Douglas and
left pelvis. X-ray treatment and one radium application to uterus was followed
by only slight regression of growth and temporary alleviation of pain lasting
approximately 6 months.
Prior to treatment with Thio-TEPA: January 1959, extensive growth involv-
ing rectum and rectovaginal wall causing stenosis of rectum, oedema of legs,EFFECT OF THIO-TEPA ON OVARIAN TUMOURS
vulva and buttocks and gross distension of veins of abdomen. She had nausea,
occasional vomiting, anorexia, frequent watery stools and sometimes loss of
control, frequency of micturition, abdominal pain and tiredness even at rest:
she was still doing a little light housework.
Treatment with Thio-TEPA started on 27. 1.59. She was given a course of
6 injections to a total of 100 mg. in 3 weeks and then one 27 mg. intra-muscularly
9 weeks after the first injection.
From the second week onwards pain and nausea decreased, appetite improved
and she gained a little in strength.
The tumour decreased in size slightly and the oedema of legs, vulva, buttocks
and the distension of abdominal veins disappeared. A rectovaginal fistual
developed in the 12th week. The distension of abdominal veins and oedema of
thighs and pain reappeared in the 14th week.
A colostomy was done and one pint of blood was transfused on 4.6.59.
The patient died 9.6.59; 19 weeks after the first injection of Thio-TEPA.
CASE 6 (FIG. 6)
Age 54. Histology: papilliferous cystadenocarcinoma.
First symptom: May 1956, pain in right lower abdomen.
15.9.58: complete removal of left ovarian growth, incomplete removal of
large friable growth of right ovary which was adherent to uterus and pelvic wall.
17. 9.58: 2 pints of blood transfused.
October/December 1958: one radium application to uterus and X-ray
treatment to pelvis.
Prior to treatment with Thio-TEPA: a large mass in the pelvis involving
uterus pressing on rectum. Constant pain in abdomen and in right shoulder for
which she required alternatively papaveretum gr. 3 or pethidine 100 mg. 4 hourly
day and night. She was very ill and confined to bed.
5. 12. 58; 2 pints of blood transfused.
Treatment with Thio-TEPA commenced on 10.2.59.
She was given at first 62-5 mg. in 7 intra-venous injections in 17 days.
From the 6th week onwards her appetite improved, she gained strength and
pain decreased. Decrease in size of the tumour commenced in the 8th week;
in the 9th week abdominal pain had almost completely disappeared. She was
discharged home and in the 12th week she could walk around and help a little in
her household.
A further 2 intra-muscular injections of 30 mg. of Thio-TEPA were given in
December. Objective and subjective improvement was maintained.
CASE 7 (FIG. 7)
Age 54. Histology: papillary carcinoma of ovary.
First symptom: October 1958, lassitude.
12. 11.58 operations: gross ascites. Omentum and peritoneum studded with
nodules, pelvis filled with growth. During the 2 months preceeding the first
injection of Thio-TEPA she needed paracentesis on 6 occasions at intervals of
0 to 21 days,
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Prior to Thio-TEPA: gross distension of abdomen due to large masses of
growth and ascites; loss of flesh; lassitude, vomiting, swelling of legs when
abdomen distended by ascites.
On 12.2.59 treatment with Thio-TEPA commenced. She was given as the
first course 150 mg. divided into 5 intra-peritoneal injections at weekly intervals.
Further injections as shown in Fig. 7.
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FIG. 6
Degree of clinical improvement - - - - - - - - - - -
Grade 1. Improvement of symptoms.
2. Disappearance of symptoms.
3. Decrease in size of tumour or decrease of ascites.
4. Clinical disappearance of ascites.
5. Disappearance oftumour, of ascites and of symptoms.
Normal activity
Restricted activity i7777T777TX
During the first 2 weeks after the first injection a paracentesis was done on
two occasions. From the 3rd week onwards ascites decreased slightly. She
gained strength, her appetite improved and she felt well.
She is doing her shopping and working part time as a typist.
Change in the size of the tumour is difficult to assess because of ascites.
The time of observation since the first injection of Thio-TEPA was 15 weeks
on June 1st 1959.
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From June 1st till October 9th 1959 she was given a further 140 mg. in 6
intra-peritoneal injections. Paracentesis abdominis was necessary once in
October 1959.
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FIG. 7
Degree of clinical improvement
Grade 1. Improvement of symptoms.
2. Disappearance of symptoms.
3. Decrease in size of tumour or decrease of ascites.
4. Clinical disappearance of ascites.
5. Disappearance of tumour, of ascites and of symptoms.
Normal activity
Restricted activity E// l7//AW
At the end of December ascites and abdominal tumour were present; she
felt quite well except at the time when a paracentesis had become necessary;
she continues doing part time work as a typist and also doing light housework.
CASE 8
Age 55. No histology.
First symptom: December 1958, swelling of abdomen.
Prior to treatment with Thio-TEPA: distension of abdomen, shortness of
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breath, loss of weight and anorexia. A paracentesis of chest and abdomen was
done r5 times during the preceding 2 months.
Examination after removal of 7 litre of fluid by paracentesis of abdomen:
large nodular growth in pelvis filling pouch of Douglas extending upwards to
the level of umbilicus. Multiple large lobulated tumour masses in abdomen.
Liver enlarged.
Treatment with Thio-TEPA commenced on 18.3.59. She was given 4
intra-peritoneal injections at weekly intervals to a total of 120 mg. Ascites was
removed by paracentesis on 4 occasions during the 6 weeks following the first
injection. From the 5th week onwards she gained strength and her appetite
improved.
In the 9th week ascites and pleural effusion increased causing dyspnoea and
therefore fluid was removed by paracentesis of chest.
The patient died on 20. 7.59, 18 weeks after the first injection of Thio-TEPA.
CASE 9
Age 45. Histology: granulosa cell carcinoma.
First symptom: November 1956, pain in left pelvis.
March 1957 : hysterectomy aind bilateral salpingo-oophorectomy for carcinoma
of ovary.
April/May 1957 : post-operative X-ray treatment to pelvis.
July 1958, secondary node in operation scar treated with X-ray.
Mass of growth in pelvis treated with X-ray November/December 1958.
Prior to treatment with Thio-TEPA: a fixed hard mass in left pelvis extending
almost to the level ofumbilicus. 4 cm. diameter subcutaneous metastatic tumour
in abdominal wall in upper end of operation scar. Liver enlarged. Slight pain
in right iliac fossa, slight backache and nausea.
Treatment with Thio-TEPA commenced on 18.3.59. She was given at first
3 injections intra-muscularly of 25 mg. each at weekly intervals.
The leucocytes dropped from 6400 to 2300 in the 3rd week; a further 25
mg. was given after the leucocytes had risen to 4200 at the end of the 6th week.
From the second week onwards she gained strength and attained a sense of
well-being. No definite change in the size of the tumour has been observed.
The patient died 4. 11 .59, 30 weeks after the first injection of Thio-TEPA.
METHOD
The crystalline Thio-TEPA was dissolved in normal saline 10 mg. per ml. and
stored no longer than 14 days in refrigeration. The route and dose in this series
varied. Ifascites was present the injections were given into the peritoneal cavity.
A small quantity of 2 per cent procaine was injected locally before giving Thio-
TEPA intra-muscularly or into the tumour. The dose varied from case to case
depeniding on the patients strength, the state of nutrition, haematological status
and on the route. From our experience we came to the conclusion that 65 to
120 mg. given in fractionated doses over three to four weeks is an effective
therapeutic dose. Intravenously Thio-TEPA was given at the rate of 7 to 10
mg. per day to a weekly maximum dose of 30 mg. Injections of Thio-TEPA are
discontinued when the graph of total leucocytes showed a downward trend
following previous injections.
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Principles of maintenance treatment are yet to be developed. We intend to
give a second course in all cases which show a good response, at the latest 3 to 5
months after the first course.
It is of great value that most cases can be treated as out patients.
EFFECT AND REACTIONS
In 4 of our cases of advanced carcinoma of the ovary, treatment with Thio-
TEPA was followed by striking temporary regression or clinical disappearance of
the growth, reduction or disappearance of ascites and marked improvement of
symptoms with return to activity and enjoyment of life. Three patients had
definite marked temporary regression of growth and improvement of symp-
toms only. The maximum duration of improvement after one course was 8
months. Second and subsequent courses were less effective than the first course.
Improvement in strength, appetite and sense of well-being, soon after the
start of treatment, was noted in all cases in whom Thio-TEPA had any clinical
effect.
Though symptoms may improve during or shortly after the second week,
decrease in size of tumour and of ascites occurs mostly after 6 to 8 weeks.
All our cases who showed a marked improvement had temporary leukopenia
following treatment.
Decrease in the number of granulocytes and platelets commenced in the
second or third week, and recovered quickly to normal. Petechiae and cutaneous
haemorrhages were observed in two cases at the time of maximumn depression of
haemopoiesis and subsided spontaneously.
The effect of Thio-TEPA on leucocytes was remarkable in case 1 in whom the
number ofleucocytes at the start of treatment was 3000, dropped to 1700 8 weeks
after treatment and rose to 7100 one week later. The fall and later the rise of
the number ofleucocytes coincided with retrogression ofgrowth and improvement
,f symptoms.
Only one case had side reactions such as nausea and vomiting. There were
no unpleasant local or general reactions in any of the other cases.
DISCUSSION
Thio-TEPA has a marked growth inhibiting effect in some cases of carcinoma
of the ovary. The effect is only temporary. Thio-TEPA does not supersede
surgery or radiotherapy in the treatment of ovarian cancer. It is, however, of
definite value in some cases in whom all other treatments have failed. In such
cases Thio-TEPA may still achieve temporary control of disease to such an extent
that the patient may enjoy a normal life and may return to normal activity for
many months. The duration of temporary control will, one can reasonably
expect, increase with greater experience and by the various means of protecting
the haemopoietic tissue.
Small repeated transfusions of blood giveni daily for a few days before, and
during treatment with Thio-TEPA, may reduce the proliferative and mitotic
activity of haemopoietic tissue to a resting phase. In the resting phase the
bone marrow may be less sensitive to a radio-mimetic and antimitotic agent.
If this concept is correct, 50 ml. of blood given daily should reduce the bone
marrow activity. A plan for investigation in this direction is in preparation.
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From what has already been done in this field, and from our own experience,
we conclude that ovarian carcinoma occupies the foremost position in the spectrum
of activity of Thio-TEPA over the whole range of malignant disease.
In many cases of advanced cancer classification by histology is often difficult
and sometimes debatable. It is likely that some cases which appear to be primary
malignant tumours may, in fact, be secondaries from a growth elsewhere. If
this is true the selective effect of Thio-TEPA on primary ovarian carcinoma
is probably higher than it appears from our series. It is of immediate interest
to coirelate sensitivity ofthe various groups ofovarian cancer to chemotherapeutic
agents with their natural history and histology, and to study each group according
to their sensitivity.
A plan ofstudy ofthe effectiveness of chemotherapy as an adjuvant to surgical
treatment of cancer has been described by Shimkin and Moore (1958).
Two investigations are being carried out using Thio-TEPA in resectable
carcinoma of stomach and nitrogen mustard in resectable cancer of lung. One of
the aims of the plan is to ascertain whether chemotherapeutic agents are more
effective when the tumours are small and clinically not obviously established.
The discovery of the effect of Thio-TEPA on carcinoma of ovary has opened
new and promising paths in the field of experimental and clinical research on
ovarian carcinoma.
SUMMARY
The effect ofThio-TEPA in 17 cases of advanced carcinoma has been described.
Objective improvement has been achieved in 8 cases, some of whom have
returned to their normal activity for several months. The clinical effect is
temporary. In all cases the effect was associated with transient leukopenia.
We are most grateful to the Lederle Laboratories, Division of Cyanamid of
Great Britain Limited, for their generous supply of Thio-TEPA and for literature
and references.
We thank Mrs. Sheila Cocks, M.S.R., Superintendent Radiographer, and the
Photographer, Mr. Brooks, for the reproduction of the graphs.
We also thank Miss Pam Martin for her secretarial help.
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